ARGXARGENX SE

Nasdaq argenx.com


$ 378.76 $ 0.84 (0.22 %)    

Tuesday, 04-Jun-2024 15:59:57 EDT
QQQ $ 454.82 $ 2.15 (0.48 %)
DIA $ 398.57 $ 1.25 (0.32 %)
SPY $ 530.36 $ 0.55 (0.1 %)
TLT $ 91.26 $ 1.04 (1.14 %)
GLD $ 225.37 $ -1.95 (-0.9 %)
$ 377.92
$ 379.64
$ 0.00 x 0
$ 0.00 x 0
$ 377.16 - $ 382.35
$ 327.73 - $ 550.76
200,746
na
22.37B
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biohaven-stock-stumbles-as-protein-degrading-drug-falls-short-of-expectations-in-early-stage-study

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

 morgan-stanley-maintains-overweight-on-argenx-lowers-price-target-to-510

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $5...

 jp-morgan-maintains-overweight-on-argenx-lowers-price-target-to-500

JP Morgan analyst James Gordon maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $560 to $500.

 hc-wainwright--co-maintains-buy-on-argenx-lowers-price-target-to-448

HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $451...

 jmp-securities-maintains-market-outperform-on-argenx-lowers-price-target-to-468

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:ARGX) with a Market Outperform and lowers the price target from...

 for-2024-argenx-expects-combined-research-and-development-and-selling-general-and-administrative-expenses-to-be-less-than-2b

FINANCIAL GUIDANCE Based on its current operating plans, argenx expects its combined Research and development and Selling, gen...

 argenx-q1-2024-gaap-eps-052-beats-074-estimate-sales-398283m-miss-405776m-estimate

argenx (NASDAQ:ARGX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.74) by 29....

 wedbush-reiterates-outperform-on-argenx-maintains-521-price-target

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $521 price target.

 hc-wainwright--co-reiterates-buy-on-argenx-maintains-451-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates argenx (NASDAQ:ARGX) with a Buy and maintains $451 price target.

 argenx-data-shows-evidence-that-vyvgart-and-vyvgart-hytrulo-deliver-transformative-results-for-patients-suffering-from-debilitating-autoimmune-diseases

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstr...

 cartesian-therapeutics-rare-disease-candidate-shows-long-lasting-benefit-over-argenxs-vyvgart-analyst-initiates-with-buy

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising ant...

 hc-wainwright--co-maintains-buy-on-argenx-maintains-451-price-target

HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and maintains $451 price target.

 argenx-announces-plan-to-continue-the-development-of-efgartigimod-primary-sjogrens-disease

RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consi...

 tesla-to-120-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION